MeSH tree: C23.550.291.656
Molecular imaging with ⁶⁸Ga-HER2 PET/CT may provide an early, targeted measure of how well treatment is working in patients with HER2-positive breast cancer.
3 hours ago
0
3
Cancer cachexia has long been one of oncology's most stubborn unsolved problems. This severe, uncontrollable wasting affects roughly half of all cancer patients. It makes treatment harder to tolerate, erodes a person's quality ...
Oct 14, 2026
0
12
The Journal of Clinical Oncology has published secondary results from the ECOG-ACRIN Cancer Research Group's CompassHER2-pCR clinical trial (EA1181, NCT04266249). The findings help identify which early-stage HER2-positive ...
Oct 6, 2026
0
18
A standardized process to evaluate patients for their readiness to be discharged from an intensive care unit (ICU) can help reduce readmissions while providing clarity and supporting collaboration among the interprofessional ...
Oct 1, 2026
0
12
Nearly half of health boards in England are deliberately delaying care for patients by imposing minimum waiting times in an attempt to manage demand and control costs, exclusive data published by The BMJ reveal.
Sep 9, 2026
0
6
Results from an early-stage clinical trial, published in Nature Communications, showed encouraging outcomes among patients with newly diagnosed cancer whose tumors had spread to distant organs. Most strikingly, one patient ...
Aug 28, 2026
0
36
Combining chemotherapy with immunotherapy before surgery for head and neck cancer is associated with significantly greater reductions in tumor size than immunotherapy alone, according to a study published online Aug. 13 in ...
Aug 21, 2026
0
3
Researchers at the Icahn School of Medicine at Mount Sinai found that a chemotherapy-free combination of four targeted therapies showed encouraging results in patients with HR-positive, HER2-positive metastatic breast cancer, ...
Aug 20, 2026
0
24
A tumor is more than its cancer cells. Immune cells, blood vessels and other surrounding tissue influence how a cancer grows and responds to treatment. Two tumors containing the same cell types can respond very differently ...
Aug 10, 2026
0
9
A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given before surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to Phase II clinical ...
Jul 30, 2026
0
11
